Patient, donor, and transplant characteristics
| . | Unmodified transplant . | T-cell–depleted transplant . | Total . |
|---|---|---|---|
| No. patients/no. samples | 31/56 | 127/275 | 158/331 |
| Donor | |||
| Related, HLA identical, no. patients/no. samples | 13/19 | 87/189 | 100/208 |
| Related, HLA nonidentical, no. patients/no. samples | 2/2 | 11/27 | 13/29 |
| Unrelated, HLA identical or nonidentical, no. patients/no. samples | 16/35 | 29/59 | 45/94 |
| Time of sample collection after transplantation, range in mo | 1-93 | 1-138 | — |
| Age | |||
| Range, y | 2.2-52.3 | 2.9-61.5 | — |
| Younger than 19 y, (%)* | 9 (29) | 15 (12) | 24 (15) |
| 19 y or older, (%) | 22 (71) | 112 (88) | 134 (85) |
| 35 y or older, (%) | 9 (29) | 72 (56) | 81 (58) |
| 40 y or older, (%) | 4 (13) | 62 (49) | 66 (42) |
| Primary disease for which allogeneic HSCT performed (no. patients) | |||
| Juvenile rheumatoid arthritis, severe | 1 | ||
| Younger than 19 y | 0 | 1 | |
| 19 y or older | 0 | 0 | |
| Thalassemia major | 1 | ||
| Younger than 19 y | 0 | 1 | |
| 19 y or older | 0 | 0 | |
| Aplastic anemia | 2 | ||
| Younger than 19 y | 0 | 0 | |
| 19 y or older | 1 | 1 | |
| Lymphohematopoietic malignancies† or myelodysplastic syndromes | 154 | ||
| Younger than 19 y | 9 | 13 | |
| 19 y or older | 21 | 111 | |
| Total body irradiation, dose (cGy), no. patients/no. samples‡ | |||
| 0 | 13/22 | ||
| Younger than 19 y | 5/10 | 1/3 | |
| 19 y or older | 3/4 | 4/5 | |
| 450 | 2/7 | ||
| Younger than 19 y | 0/0 | 2/7 | |
| 19 y or older | 0/0 | 0/0 | |
| 1350 | 13/29 | ||
| Younger than 19 y | 3/9 | 0/0 | |
| 19 y or older | 10/20 | 0/0 | |
| 1375 | 36/70 | ||
| Younger than 19 y | 0/0 | 3/5 | |
| 19 y or older | 6/7 | 27/58 | |
| 1410 | 12/25 | ||
| Younger than 19 y | 0/0 | 0/0 | |
| 19 y or older | 1/1 | 11/24 | |
| 1500 | 82/178 | ||
| Younger than 19 y | 1/2 | 9/24 | |
| 19 y or older | 2/3 | 70/149 | |
| ATG graft rejection prophylaxis | |||
| Yes (%)* | 0 (0) | 105 (83) | 105 |
| No (%) | 31 (100) | 22 (17) | 53 |
| TRECs sampled after donor leukocyte infusions (DLI), no. patients/no. samples | |||
| No DLI | 139/296 | ||
| Younger than 19 y | 9/21 | 14/40 | |
| 19 y or older | 23/35 | 93/202 | |
| Prior DLI | 19/35 | ||
| Younger than 19 y | 0/0 | 1/1 | |
| 19 y or older | 0/0 | 18/34 |
| . | Unmodified transplant . | T-cell–depleted transplant . | Total . |
|---|---|---|---|
| No. patients/no. samples | 31/56 | 127/275 | 158/331 |
| Donor | |||
| Related, HLA identical, no. patients/no. samples | 13/19 | 87/189 | 100/208 |
| Related, HLA nonidentical, no. patients/no. samples | 2/2 | 11/27 | 13/29 |
| Unrelated, HLA identical or nonidentical, no. patients/no. samples | 16/35 | 29/59 | 45/94 |
| Time of sample collection after transplantation, range in mo | 1-93 | 1-138 | — |
| Age | |||
| Range, y | 2.2-52.3 | 2.9-61.5 | — |
| Younger than 19 y, (%)* | 9 (29) | 15 (12) | 24 (15) |
| 19 y or older, (%) | 22 (71) | 112 (88) | 134 (85) |
| 35 y or older, (%) | 9 (29) | 72 (56) | 81 (58) |
| 40 y or older, (%) | 4 (13) | 62 (49) | 66 (42) |
| Primary disease for which allogeneic HSCT performed (no. patients) | |||
| Juvenile rheumatoid arthritis, severe | 1 | ||
| Younger than 19 y | 0 | 1 | |
| 19 y or older | 0 | 0 | |
| Thalassemia major | 1 | ||
| Younger than 19 y | 0 | 1 | |
| 19 y or older | 0 | 0 | |
| Aplastic anemia | 2 | ||
| Younger than 19 y | 0 | 0 | |
| 19 y or older | 1 | 1 | |
| Lymphohematopoietic malignancies† or myelodysplastic syndromes | 154 | ||
| Younger than 19 y | 9 | 13 | |
| 19 y or older | 21 | 111 | |
| Total body irradiation, dose (cGy), no. patients/no. samples‡ | |||
| 0 | 13/22 | ||
| Younger than 19 y | 5/10 | 1/3 | |
| 19 y or older | 3/4 | 4/5 | |
| 450 | 2/7 | ||
| Younger than 19 y | 0/0 | 2/7 | |
| 19 y or older | 0/0 | 0/0 | |
| 1350 | 13/29 | ||
| Younger than 19 y | 3/9 | 0/0 | |
| 19 y or older | 10/20 | 0/0 | |
| 1375 | 36/70 | ||
| Younger than 19 y | 0/0 | 3/5 | |
| 19 y or older | 6/7 | 27/58 | |
| 1410 | 12/25 | ||
| Younger than 19 y | 0/0 | 0/0 | |
| 19 y or older | 1/1 | 11/24 | |
| 1500 | 82/178 | ||
| Younger than 19 y | 1/2 | 9/24 | |
| 19 y or older | 2/3 | 70/149 | |
| ATG graft rejection prophylaxis | |||
| Yes (%)* | 0 (0) | 105 (83) | 105 |
| No (%) | 31 (100) | 22 (17) | 53 |
| TRECs sampled after donor leukocyte infusions (DLI), no. patients/no. samples | |||
| No DLI | 139/296 | ||
| Younger than 19 y | 9/21 | 14/40 | |
| 19 y or older | 23/35 | 93/202 | |
| Prior DLI | 19/35 | ||
| Younger than 19 y | 0/0 | 1/1 | |
| 19 y or older | 0/0 | 18/34 |
Percentage calculated relative to the total number of patients in the column category.
Includes patients allografted as treatment for acute myelogenous leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, non-Hodgkin lymphoma, and a single case of multiple myeloma.
All preparative regimens were myeloablative and included either radiation and chemotherapy or chemotherapy alone.